Pichia Patents (Class 435/254.23)
-
Publication number: 20140037619Abstract: The invention provides methods, compositions and kits for treating and or preventing an HIV infection. For example, HIV envelope-like polypeptides (wild-type HIV polypeptides and mimotopes) may be administered to an individual so as to induce a protective immune response to HIV. Alternatively, antibodies directed to the HIV envelope-like polypeptides may be administered to an individual to treat or prevent an HIV infection and/or one or more symptoms associated with the infection (e.g., AIDS).Type: ApplicationFiled: June 10, 2013Publication date: February 6, 2014Applicant: DANA-FARBER CANCER INSTITUTEInventors: Ruth M. Ruprecht, Michael Humbert
-
Publication number: 20140038842Abstract: Novel materials and methods useful for displaying polypeptides on the surface of a cell are provided, including cell surface proteins fused to a PDZ domain peptide and antibodies fused to PDZ-binding peptides.Type: ApplicationFiled: December 28, 2011Publication date: February 6, 2014Applicant: XOMA TECHNOLOGYInventors: Eric M. Tam, Isaac J. Rondon, Chao B. Huang, Violet Votin
-
Publication number: 20140038268Abstract: The present invention is related to a recombinant host cell, in particular a yeast cell, comprising a dihydroxy-acid dehydratase polypeptide. The invention is also related to a recombinant host cell having increased specific activity of the dihydroxy-acid dehydratase polypeptide as a result of increased expression of the polypeptide, modulation of the Fe—S cluster biosynthesis of the cell, or a combination thereof. The present invention also includes methods of using the host cells, as well as, methods for identifying polypeptides that increase the flux in an Fe—S cluster biosynthesis pathway in a host cell.Type: ApplicationFiled: March 15, 2013Publication date: February 6, 2014Applicant: BUTAMAX(TM) ADVANCED BIOFUELS LLCInventor: Butamax(TM) Advanced Biofuels LLC
-
Patent number: 8642298Abstract: The invention relates to a nucleic acid sequence encoding an itaconate transporting Major Facilitator Superfamily Transporter (MFST) gene sequence and the protein encoded thereby. Preferably said sequence is the nucleic acid that comprises the sequence of ATEG_09972.1 of Aspergillus terreus or homologues thereof. Overexpression of the protein enhances the production of itaconic acid in microorganisms.Type: GrantFiled: March 4, 2009Date of Patent: February 4, 2014Assignee: Nederlandse Organisatie Voor Toegepast—Natuurwetenschappelijk Onderzoek TnoInventors: Maria Johanna Van Der Werf, Peter Jan Punt
-
Publication number: 20140030770Abstract: The present invention relates to isolated polypeptides having cellobiohydrolase activity and polynucleotides encoding the polypeptides. The invention also relates to nucleic acid constructs, vectors, and host cells comprising the polynucleotides as well as methods of producing and using the polypeptides.Type: ApplicationFiled: January 26, 2012Publication date: January 30, 2014Applicant: NOVOZYMES INC.Inventor: Nikolaj Spodsberg
-
Publication number: 20140030761Abstract: The present disclosure provides methods for producing expression constructs comprising linking a plurality of unlinked nucleic acids, including nucleic acid encoding a marker protein.Type: ApplicationFiled: October 3, 2011Publication date: January 30, 2014Applicant: CSL LIMITEDInventors: Con Panousis, Chao-Guang Chen
-
MICROORGANISMS AND METHODS FOR PRODUCTION OF 4-HYDROXYBUTYRATE, 1,4-BUTANEDIOL AND RELATED COMPOUNDS
Publication number: 20140030779Abstract: The invention provides non-naturally occurring microbial organisms having a 4-hydroxybutyrate pathway and being capable of producing 4-hydroxybutyrate, wherein the microbial organism comprises one or more genetic modifications. The invention additionally provides methods of producing 4-hydroxybutyrate or related products using the microbial organisms.Type: ApplicationFiled: June 3, 2013Publication date: January 30, 2014Applicant: GENOMATICA, INC.Inventors: Priti PHARKYA, Anthony P. BURGARD, Stephen J. VAN DIEN, Robin E. OSTERHOUT, Mark J. BURK, John D. TRAWICK, Michael P. KUCHINSKAS, Brian STEER -
Publication number: 20140030776Abstract: A group of bacterial dihydroxy-acid dehydratases having a [2Fe-2S] cluster was discovered. Bacterial [2Fe-2S] DHADs were expressed as heterologous proteins in bacteria and yeast cells, providing DHAD activity for conversion of 2,3-dihydroxyisovalerate to ?-ketoisovalerate or 2,3-dihydroxymethylvalerate to ?-ketomethylvalerate. Isobutanol and other compounds may be synthesized in pathways that include bacterial [2Fe-2S] DHAD activity.Type: ApplicationFiled: March 15, 2013Publication date: January 30, 2014Applicant: Butamax(TM) Advanced Biofuels LLCInventor: Butamax(TM) Advanced Biofuels LLC
-
Publication number: 20140030287Abstract: The present invention relates to peptides of the enolase protein from Staphylococcus aureus as well as nucleic acid and nucleic acid sequence homologues encoding the peptides. The present invention also relates to a composition, particularly a S. aureus vaccine, comprising one or more of the enolase peptides described herein or a fragment, derivative or variant thereof capable of generating an immune response that induces a protective antibody response or opsonophagocytic activity of human neutrophils for S. aureus. The present invention also encompasses methods of treating and/or reducing the likelihood of a Staphylococcus infection by administering a composition of the invention.Type: ApplicationFiled: October 3, 2013Publication date: January 30, 2014Inventors: TESSIE B. MCNEELY, LESLIE COPE, SHARON SMITH, AMITA JOSHI, IRENE PAK, ARTHUR FRIDMAN
-
Publication number: 20140026261Abstract: The present invention provides isolated polypeptides having cellulolytic enhancing activity and isolated polynucleotides encoding the polypeptides. The invention also provides nucleic acid constructs, vectors, and host cells comprising the polynucleotides as well as methods of producing and using the polypeptides.Type: ApplicationFiled: April 25, 2012Publication date: January 23, 2014Inventors: Yu Zhang, Lan Tang, Svend Hostgaard Bang Henriksen
-
Publication number: 20140024862Abstract: A genetically engineered micro-organism having an operative metabolic pathway producing cinnamoyl-CoA and producing pinosylvin therefrom by the action of a stilbene synthase is used for pinosylvin production. Said cinnamic acid may be formed from L-phenylalanine by a L-phenylalanine ammonia lyase (PAL) which is one accepting phenylalanine as a substrate and producing cinammic acid therefrom, preferably such that if the PAL also accepts tyrosine as a substrate and forms coumaric acid therefrom, the ratio Km(phenylalanine)/Km(tyrosine) for said PAL is less than 1:1 and if said micro-organism produces a cinammate-4-hydroxylase enzyme (C4H), the ratio Kcat(PAL)/Kcat(C4H) is at least 2:1.Type: ApplicationFiled: January 2, 2013Publication date: January 23, 2014Inventors: Michael Katz, Jochen Forster, Helga David, Hans Peter Schmidt, Malin Sendelius, Sara Peterson Bjorn, Thomas Thomasen Durhuus
-
Publication number: 20140023644Abstract: The present disclosure relates, in general, to materials and methods for antibodies specific for transforming growth factor beta (TGF?), including TGF?1, TGF?2 and TGF?3, and uses of these antibodies in the treatment of subjects having cancer, an eye disease, condition or disorder, fibrosis, including ophthalmic fibrosis or fibrosis of the eye, and other conditions or disorders related to TGF? expression.Type: ApplicationFiled: September 26, 2013Publication date: January 23, 2014Applicant: XOMA Technology Ltd.Inventors: Daniel Bedinger, Shireen S. Khan, Amer Mirza, Ajay J. Narasimha, Toshihiko Takeuchi
-
Publication number: 20140024094Abstract: Yeast cells with reduced activity of certain enzymes involved in branched chain amino acid biosynthesis in yeast mitochondria are described. Target enzymes include threonine deaminase, isopropylmalate synthase, and optionally branched chain amino acid transaminase.Type: ApplicationFiled: May 8, 2013Publication date: January 23, 2014Applicant: Butamax Advanced Biofuels LLCInventor: Larry Cameron ANTHONY
-
Publication number: 20140024086Abstract: The subject invention pertains to the discovery that the NADH-dependent propanediol oxidoreductase (FucO) can reduce furfural. This allows for a new approach to improve furfural tolerance in bacterial and/or yeast cells used to produce desired products. Thus, novel biocatalysts (bacterial, fungal or yeast cells) exhibiting increased tolerance to furfural and 5-hydroxymethylfurfural (5-HMF) are provided as are methods of making and using such biocatalysts for the production of a desired product.Type: ApplicationFiled: March 29, 2012Publication date: January 23, 2014Applicant: UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC.Inventors: Elliot N. Miller, Xueli Zhang, Lorraine P. Yomano, Xuan Wang, Keelnatham T. Shanmugam, Lonnie O'Neal Ingram
-
Publication number: 20140023641Abstract: The present invention relates to antibodies with specificity for granulocyte-macrophage colony stimulating factor (GM-CSF). More particularly, the invention relates to humanized monoclonal antibodies that bind specifically to human GM-CSF with high affinity. The invention also relates to nucleic acids encoding the antibodies, vectors for expression of these nucleic acids, and host cells for producing said antibodies. Further, the invention relates to the use of said antibodies in the diagnosis or treatment of autoimmune or inflammatory diseases.Type: ApplicationFiled: November 17, 2011Publication date: January 23, 2014Applicant: Merck Serono S.A.Inventors: Laurent Magnenant, Olivier Leger, Charles Mackay, David Georges Zahra
-
Publication number: 20140024095Abstract: Improved haa1 transcriptional regulatory proteins, polynucleotides encoding improved haa1 transcriptional regulatory proteins and vectors and cells thereof are provided, as well as methods for converting a cellulose-containing biomass feedstock to ethanol using improved haa1 transcriptional regulatory proteins and cells expressing heterologous haa1 transcriptional regulatory proteins as disclosed herein.Type: ApplicationFiled: July 22, 2013Publication date: January 23, 2014Applicant: EdeniQ, Inc. (027586)Inventors: Kenneth Zahn, Sandra Jacobson
-
Publication number: 20140017737Abstract: The present invention relates to variants of a parent cellobiohydrolase II. The present invention also relates to polynucleotides encoding the variants; nucleic acid constructs, vectors, and host cells comprising the polynucleotides; and methods of using the variants.Type: ApplicationFiled: September 23, 2013Publication date: January 16, 2014Inventor: Mark Wogulis
-
Publication number: 20140017695Abstract: A method of detecting and isolating cells that produce a secreted protein of interest (POI) that has a T cell receptor variable domain, comprising: a) constructing a cell line transiently or stably expressing a cell surface capture molecule, which binds the POI, by transfecting the cell line with a nucleic acid that encodes such cell surface capture molecule; b) transfecting said cell simultaneously or subsequently with a second nucleic acid that encodes a POI wherein such POI is secreted; c) detecting the surface-displayed POI by contacting the cells with a detection molecule, which binds the POI; and d) isolating cells based on the detection molecule.Type: ApplicationFiled: January 10, 2013Publication date: January 16, 2014Applicant: REGENERON PHARMACEUTICALS, INC.Inventor: REGENERON PHARMACEUTICALS, INC.
-
Publication number: 20140011236Abstract: The present invention provides, in part, promoters for recombinant expression of polypeptides in host cells such as Pichia pastoris as well as methods of use thereof.Type: ApplicationFiled: March 15, 2012Publication date: January 9, 2014Inventors: Robert Davidson, Bianka Prinz, I-Ming Wang, Stephen Hamilton, Ming-Tang Chen, Brian Mickus
-
Publication number: 20140010809Abstract: The invention relates to novel binding domain-immunoglobulin fusion proteins that feature a binding domain for a cognate structure such as an antigen, a counterreceptor or the like, a wild-type IgG1, IGA or IgE hinge region polypeptide or a mutant IgG1 hinge region polypeptide having either zero, one or two cysteine residues, and immunoglobulin CH2 and CH3 domains, and that are capable of ADCC and/or CDC while occurring predominantly as polypeptides that are compromised in their ability to form disulfide-linked multimers. The fusion proteins can be recombinantly produced at high express levels. Also provided are related compositions and methods, including cell surface forms of the fusion proteins and immunotherapeutic applications of the fusion proteins and of polynucleotides encoding such fusion proteins.Type: ApplicationFiled: March 15, 2013Publication date: January 9, 2014Inventors: Jeffrey A. LEDBETTER, Martha Hayden-Ledbetter
-
Publication number: 20140011262Abstract: The present invention relates to methods for producing a polypeptide, comprising: (a) cultivating a fungal host cell in a medium conducive for the production of the polypeptide, wherein the fungal host cell comprises a nucleic acid construct comprising a first nucleotide sequence encoding a signal peptide operably linked to a second nucleotide sequence encoding the polypeptide, wherein the first nucleotide sequence is foreign to the second nucleotide sequence and the 3? end of the first nucleotide sequence is immediately upstream of the initiator codon of the second nucleotide sequence. The present invention also relates to the isolated signal peptide sequences and to constructs, vectors, and fungal host cells comprising the signal peptide sequences operably linked to nucleotide sequences encoding polypeptides.Type: ApplicationFiled: July 18, 2013Publication date: January 9, 2014Applicant: NOVOZYMES, INC.Inventors: Suchindra Maiyuran, Ana Fidantsef, Howard Brody
-
Publication number: 20140004526Abstract: The invention relates to suitable screening strategies for evaluating various candidate promoters for differential gene expression during the propagation and production phases of a fermentation process. The invention also relates to recombinant host cells that comprise identified promoter nucleic acid sequences and methods for producing fermentation products employing the same.Type: ApplicationFiled: December 28, 2012Publication date: January 2, 2014Applicant: Butamax™ Advanced Biofuels LLCInventor: Butamax™ Advanced Biofuels LLC
-
Publication number: 20130344076Abstract: The present application provides the amino acid and nucleic acid sequences of heavy and light chain complementarity determining regions of a cancer specific antibody directed to an epitope of variant Nuclear Factor Kappa-B inhibitor beta (NFKBIB). In addition, the application provides cancer specific antibodies and immunoconjugates comprising the cancer specific antibody attached to a toxin or a label, and methods of uses thereof. The application also relates to diagnostic methods and kits using the cancer specific antibodies herein. Further, the application provides novel cancer-associated epitopes and antigens of variant NFKBIB, and uses thereof.Type: ApplicationFiled: March 26, 2013Publication date: December 26, 2013Applicant: Viventia Bio Inc.Inventors: Francina C. CHAHAL, Jeannick CIZEAU
-
Publication number: 20130345398Abstract: The present invention relates to the construction, expression, and purification of synthetic or recombinant light chain (LC) botulinum neurotoxin genes from all botulinum neurotoxin serotypes. The methods of the invention can provide 1.1 g of the LC per liter of culture. The LC product is stable and proteolytically active. Methods of using the products of the invention are described.Type: ApplicationFiled: March 23, 2012Publication date: December 26, 2013Inventors: Leonard A Smith, Melody Jensen
-
Publication number: 20130344086Abstract: The invention provides antibodies that are modified to reduce aggregration propensity, and methods of producing such antibodies. The present invention also provides particularly stable and soluble scFv antibodies and Fab fragments specific for TNF, which comprise specific light chain and heavy chain sequences that are optimized for stability, solubility, in vitro and in vivo binding of TNF, and low immunogenicity. The nucleic acids, vectors and host cells for expression of the recombinant antibodies of the invention, methods for isolating them and the use of said antibodies in medicine are also disclosed.Type: ApplicationFiled: August 28, 2013Publication date: December 26, 2013Applicant: ESBATech, An Alcon Biomedical Research Unit LLCInventors: Leonardo Jose Borras, David Urech
-
Publication number: 20130336925Abstract: The invention provides fusion proteins having improved bioactivity comprising a first polypeptide fusion partner and a second polypeptide fusion partner wherein the first fusion partner is linked to the second fusion partner by a mucin-domain polypeptide linker and wherein the bioactivity of the fusion protein of the invention is improved as compared to fusion of the first polypeptide fusion partner and the second polypeptide fusion partner in the absence of the mucin-domain polypeptide linker. Mucin-domain polypeptide linkers comprise a mucin domain that is rich in potential glycosylation sites, and has a high content of serine and/or threonine and proline, which can represent greater than 40% of the amino acids within the mucin domain and further comprise at least about 60% of its mass due to the glycans.Type: ApplicationFiled: June 6, 2013Publication date: December 19, 2013Applicant: Alkermes, Inc.Inventors: JUAN ALVAREZ, LESLIE A. MCSWEENEY
-
Publication number: 20130336956Abstract: The present invention relates to methods for the manufacture, purification, formulation, and use of biologically active recombinant elastase proteins. Described are recombinant methods for producing therapeutically useful elastase proteins, as are pharmaceutical compositions comprising said elastase proteins. Novel recombinant elastase proteins and protein preparations are also disclosed. Methods are described for treating and preventing diseases of biological conduits using pharmaceutical compositions containing the elastase proteins of the invention.Type: ApplicationFiled: August 2, 2013Publication date: December 19, 2013Applicant: Proteon Therapeutics, Inc.Inventors: F. Nicholas Franano, Kimberly S. Bland, Marco D. Wong, Bee C. Ding
-
Publication number: 20130337478Abstract: The present disclosure relates to a method for the purification of a human IgG-CH1 domain comprising molecule using an antigen-binding protein that is capable of binding to an epitope that is comprised in the CH1 domain of each of human IgG1, human IgG2, human IgG3 and human IgG4. The disclosure further relates to the antigen-binding proteins that can be used in the method of the disclosure. The frame-work regions of the antigen-binding proteins of the invention preferably correspond to those of antibodies that naturally are devoid of light chains as may e.g. be found in camelids. The disclosure further relates to nucleic acids that encode such antigen-binding proteins, to immunoadsorbent materials that comprise such proteins, and to the uses of such immunoadsorbent materials for the purification of IgG-CH1 domain containing molecules from a variety of species.Type: ApplicationFiled: January 31, 2012Publication date: December 19, 2013Applicant: BAC IP B.V.Inventors: Wilhelmus Josephus Johanna Hermans, Sven Blokland, Maria Anna van Kesteren, Johanna Magaretha Horrevoets, Franciscus Johan Marinus Detmers
-
Publication number: 20130330784Abstract: The invention relates to temperature-stable polypeptides with ?-pyranosidase activity. The polypeptide substrates include ?-glucopyranosides und ?-xylopyranosides. Said polypeptides can be expressed alone or as fusion proteins for example in yeast or bacteria and subsequently purified. The polypeptides according to said invention can be used alone or in a mixture with other enzymes for the degradation of plant raw materials, among others for the enzymatic degradation of biomass containing lignocellulose, in particular hemicellulose and the hemicellulose component xylan. Said enzymes are suitable for use in textile processing, as an additive of detergents, or in the food or feed industry.Type: ApplicationFiled: October 26, 2011Publication date: December 12, 2013Applicant: CLARIANT PRODUKTE (DEUTSCHLAND) GMBHInventors: Christoph Reisinger, Farah Qoura, Barbara Klippel, Garabed Antranikian
-
Publication number: 20130333072Abstract: The present invention relates to isolated polypeptides having glucoamylase activity and isolated polynucleotides encoding the polypeptides. The invention also relates to nucleic acid constructs, vectors, and host cells comprising the polynucleotides as well as methods of producing and using the polypeptides.Type: ApplicationFiled: November 30, 2010Publication date: December 12, 2013Applicants: Novozymes North America, Inc., Novozymes A/SInventors: Sara Landvik, Keiichi Ayabe, Guillermo Coward-Kelly
-
IDENTIFICATION OF ISOPRENE SYNTHASE VARIANTS WITH IMPROVED PROPERTIES FOR THE PRODUCTION OF ISOPRENE
Publication number: 20130330796Abstract: The invention provides for compositions and methods for producing isoprene using isoprene synthase variants with improved properties.Type: ApplicationFiled: March 13, 2013Publication date: December 12, 2013Applicants: The Goodyear Tire & Rubber Company, DANISCO US INC.Inventors: Zachary Q. BECK, David A. ESTELL, Jeffrey V. MILLER, James NGAI, Christopher L. RIFE, Derek H. WELLS -
Publication number: 20130323240Abstract: The present invention is directed to antigen-binding polypeptides, or variants or derivatives thereof which specifically bind the LIGHT polypeptide. The invention is also directed to methods of making and using such antibodies specifically in the treatment or diagnosis of immune, inflammatory and malignant diseases or conditions (e.g. inflammatory bowel disease; Crohn's disease, ulcerative colitis, multiple sclerosis, rheumatoid arthritis and transplantation).Type: ApplicationFiled: August 8, 2013Publication date: December 5, 2013Applicant: TEVA Biopharmaceuticals USA, Inc.Inventors: Rodger Smith, Palanisamy Kanakaraj, Bridget A. Cooksey, Viktor Roschke, Craig Rosen
-
Publication number: 20130323766Abstract: The present invention provides for novel metabolic pathways to convert biomass and other carbohydrate sources to malonyl-CoA derived products, such as hydrocarbons and other bioproducts, under anaerobic conditions and with the net production of ATP. More specifically, the invention provides for a recombinant microorganism comprising one or more native and/or heterologous enzymes that function in one or more engineered metabolic pathways to achieve conversion of a carbohydrate source to, e.g., long-chain hydrocarbons and hydrocarbon derivatives, wherein the one or more native and/or heterologous enzymes is activated, upregulated, downregulated, or deleted. The invention also provides for processes to convert biomass to malonyl-CoA derived products which comprise contacting a carbohydrate source with a recombinant microorganism of the invention.Type: ApplicationFiled: August 5, 2011Publication date: December 5, 2013Applicant: Mascoma CorporationInventors: William Ryan Sillers, Shital A. Tripathi, Arthur J. Shaw, Aaron Argyros, David A. Hogsett
-
Patent number: 8597906Abstract: Described herein are methods and genetically engineered cells useful for producing an altered N-glycosylation form of a target molecule. Also described are methods and molecules with altered N-glycosylation useful for treating a variety of disorders such as metabolic disorders.Type: GrantFiled: April 26, 2011Date of Patent: December 3, 2013Assignees: Oxyrane UK Limited, VIB vzw, Universiteit GentInventors: Nico Luc Marc Callewaert, Wouter Vervecken, Karen Jacqueline Marcel De Pourcq, Steven Christian Jozef Geysens, Mouna Guerfal
-
Publication number: 20130315911Abstract: The present invention relates to antagonizing the activity of IL-17A, IL-17F and IL-23 using bispecific antibodies that comprise a binding entity that is cross-reactive for IL-17A and IL-17F and a binding entity that binds IL-23p19. The present invention relates to novel bispecific antibody formats and methods of using the same.Type: ApplicationFiled: May 21, 2013Publication date: November 28, 2013Applicant: Bristol-Myers Squibb CompanyInventors: Brenda L. Stevens, Alison Witte, Mark W. Rixon, Josephine M. Cardarelli, Thomas D. Kempe, Scott R. Presnell, Mohan Srinivasan, Susan C. Wong, Guodong Chen, Hui Wei, Stanley R. Krystek, Lumelle A. Schneeweis, Paul O. Sheppard, Indrani Chakraborty
-
Publication number: 20130316409Abstract: The invention relates to nitrilases and to nucleic acids encoding the nitrilases. In addition methods of designing new nitrilases and method of use thereof are also provided. The nitrilases have increased activity and stability at increased pH and temperature.Type: ApplicationFiled: November 12, 2012Publication date: November 28, 2013Applicant: VERENIUM CORPORATIONInventor: VERENIUM CORPORATION
-
Publication number: 20130315918Abstract: Anti-VEGF antibodies and variants thereof, including those having high affinity for binding to VEGF, are disclosed. Also provided are methods of using phage display technology with naïve libraries to generate and select the anti-VEGF antibodies with desired binding and other biological activities. Further contemplated are uses of the antibodies in research, diagnostic and therapeutic applications.Type: ApplicationFiled: June 27, 2013Publication date: November 28, 2013Applicant: Genentech, Inc.Inventors: GERMAINE FUH, HANS-PETER GERBER, WEI-CHING LIANG, FREDERIC FELLOUSE, SACHDEV S. SIDHU, CHRISTIAN WIESMANN
-
Publication number: 20130316962Abstract: The present invention relates to novel muteins derived from human lipocalin 2 (hNGAL) and related proteins that bind a given non-natural ligand with detectable affinity. The invention also related to corresponding nucleic acid molecules encoding such a mutein and to a method for their generation. The invention further relates to a method for producing such a mutein. Furthermore, the invention is directed to a pharmaceutical composition comprising such a lipocalin mutein as well as to various uses of the mutein.Type: ApplicationFiled: April 9, 2013Publication date: November 28, 2013Applicant: TECHNISCHE UNIVERSITÄT MÜNCHENInventors: Arne Skerra, Andreas Eichinger, Hyun-Jin Kim
-
Publication number: 20130316404Abstract: The present invention relates to a polypeptide having interleukin-10 function, comprising two interleukin-10 monomer subunits covalently linked by a linker. The present invention further relates to a nucleic acid molecule encoding the polypeptide of the invention, a vector comprising said nucleic acid molecule, a non-human host transformed with the nucleic acid molecule or the vector of the invention as well as a method for the production of a recombinant polypeptide of the invention. The present invention further relates to a pharmaceutical composition as well as to the polypeptide, the nucleic acid molecule, the vector or the host or host cell of the invention for use in treating and/or preventing inflammatory diseases.Type: ApplicationFiled: November 25, 2011Publication date: November 28, 2013Applicants: THE UNIVERSITY OF MANCHESTER, TECHNISCHE UNIVERSITÄT DRESDENInventors: Axel Roers, Sebastian Lanvermann, Werner Müller
-
Publication number: 20130316437Abstract: The present disclosure relates to host cells containing a recombinant polynucleotide encoding a polypeptide where the polypeptide transports cellodextrin into the cell. The present disclosure further relates to methods of increasing transport of cellodextrin into a cell, methods of increasing growth of a cell on a medium containing cellodextrin, methods of co-fermenting cellulose-derived and hemicellulose-derived sugars, and methods of making hydrocarbons or hydrocarbon derivatives by providing a host cell containing a recombinant polynucleotide encoding a polypeptide where the polypeptide transports cellodextrin into the cell.Type: ApplicationFiled: March 13, 2013Publication date: November 28, 2013Applicants: The Regents of the University of California, BP Corporation North America Inc., The Board of Trustees of the University of IllinoisInventors: N. Louise GLASS, Chaoguang Tian, William T. Beeson, Huimin Zhao, Jing Du, Jin Ho Choi, James H. Doudna Cate, Jonathan M. Galazka, Suk-Jin Ha, Yong-Su Jin, Soo Rin Kim, Sijin Li, Xiaomin Yang
-
Publication number: 20130316426Abstract: The invention provides a method of producing acrylic acid. The method includes contacting fumaric acid with a sufficient amount of ethylene in the presence of a cross-metathesis transformation catalyst to produce about two moles of acrylic acid per mole of fumaric acid. Also provided is an acrylate ester. The method includes contacting fumarate diester with a sufficient amount of ethylene in the presence of a cross-metathesis transformation catalyst to produce about two moles of acrylate ester per mole of fumarate diester. An integrated process for process for producing acrylic acid or acrylate ester is provided which couples bioproduction of fumaric acid with metathesis transformation. An acrylic acid and an acrylate ester production also is provided.Type: ApplicationFiled: May 3, 2013Publication date: November 28, 2013Applicant: Genomatica, Inc.Inventor: Genomatica, Inc.
-
Patent number: 8591896Abstract: The present invention relates to polypeptides directed against or specifically binding to chemokine receptor CXCR2 and in particular to polypeptides capable of modulating signal transduction from CXCR2. The invention also relates to nucleic acids, vectors and host cells capable of expressing the polypeptides of the invention, pharmaceutical compositions comprising the polypeptides and uses of said polypeptides and compositions for treatment of diseases involving aberrant functioning of CXCR2.Type: GrantFiled: November 7, 2011Date of Patent: November 26, 2013Assignee: Novartis AGInventors: Michelle Bradley, Zarin Brown, Steven John Charlton, Karen Cromie, Bruno Dombrecht, Soren Steffensen, Gino Van Heeke
-
Publication number: 20130309736Abstract: The present application provides genetically modified yeast cell comprising an active malate fermentation pathway and/or an active fumarate fermentation pathway, as well as methods of using these cells to produce malate and/or fumarate.Type: ApplicationFiled: January 25, 2012Publication date: November 21, 2013Applicant: CARGILL, INCORPORATEDInventors: Kenneth R. Finley, Jeanette M. Huryta, Beth M. Mastel, Thomas W. McMullin, Gregory M. Poynter, Brian J. Rush, Kevin T. Watts, Arlene M. Fosmer
-
Publication number: 20130309752Abstract: The present disclosure generally relates to polypeptides having colanic acid-degrading activity and methods of using the same. Polynucleotides encoding such polypeptides are also described. The polypeptides may be used, for example, in processes for degrading colanic acid, processes for the removal of endotoxins from biological samples, and processes for purifying plasmid DNA.Type: ApplicationFiled: July 30, 2013Publication date: November 21, 2013Applicant: GRADALIS, INC,Inventor: Nancy Smyth Templeton
-
Publication number: 20130309751Abstract: The present invention relates to isolated polypeptides having phospholipase C activity and isolated polynucleotides encoding the polypeptides. The invention also relates to nucleic acid constructs, vectors, and host cells comprising the polynucleotides as well as methods of producing and using the polypeptides.Type: ApplicationFiled: November 9, 2011Publication date: November 21, 2013Applicant: Novozymes A/SInventors: Lan Tang, Ye Liu, Kim Borch, Jesper Brask
-
Publication number: 20130309747Abstract: The present invention relates to a novel enhancer of protein production in host cells. It discloses a vector for expressing recombinant proteins in these cells, comprising a nucleotide sequence encoding a) a secretion peptidic signal, b) a 6-methylguanine-DNA-methyltransferase enzyme (MGMT, EC 2.1.1.63), a mutant or a catalytic domain thereof, and c) a recombinant protein. Said MGMT enzyme is preferably the so-called SNAP protein.Type: ApplicationFiled: December 9, 2011Publication date: November 21, 2013Inventors: Philippe Despres, Sylvie Paulous, Elodie Crublet
-
Publication number: 20130309726Abstract: The present invention relates to combinatorial variants of a parent glucoamylase that have altered properties for reducing the synthesis of condensation products during hydrolysis of starch. Accordingly the variants of a parent glucoamylase are suitable such as for use within brewing and glucose syrup production. Also disclosed are DNA constructs encoding the variants and methods of producing the glucoamylase variants in host cells.Type: ApplicationFiled: June 30, 2011Publication date: November 21, 2013Applicant: DUPONT NUTRITION BIOSCIENCES APSInventors: Peter Edvard Degn, Richard R. Bott, Casper Willem Vroemen, Martijn Silvan Scheffers, Wolfgang Aehle, Elin Petersen
-
Publication number: 20130302399Abstract: The present invention is directed to antibodies and fragments thereof having binding specificity for PCSK9. Another embodiment of this invention relates to the antibodies described herein, and binding fragments thereof, comprising the sequences of the VH, VL and CDR polypeptides described herein, and the polynucleotides encoding them. The invention also contemplates conjugates of anti-PCSK9 antibodies and binding fragments thereof conjugated to one or more functional or detectable moieties. The invention also contemplates methods of making said anti-PCSK9 antibodies and binding fragments thereof. Embodiments of the invention also pertain to the use of anti-PCSK9 antibodies, and binding fragments thereof, for the diagnosis, assessment and treatment of diseases and disorders associated with PCSK9.Type: ApplicationFiled: March 12, 2013Publication date: November 14, 2013Inventors: Andrew Lawrence Feldhaus, Leon F. Garcia-Martinez, Benjamin H. Dutzar, Ethan Wayne Ojala, Brian Robert Kovacevich, Katie Olson, Pei Fan, Jens Billgren, Erica Ann Stewart, Corinne C. Akatsuka, Patricia Dianne McNeill, Danielle Marie Mitchell, Dan Scott Allison, John A. Latham
-
Publication number: 20130302859Abstract: The present disclosure provides engineered polypeptides having imine reductase activity, polynucleotides encoding the engineered imine reductases, host cells capable of expressing the engineered imine reductases, and methods of using these engineered polypeptides with a range of ketone and amine substrate compounds to prepare secondary and tertiary amine product compounds.Type: ApplicationFiled: May 9, 2013Publication date: November 14, 2013Applicant: CODEXIS,INC.Inventors: CHEN Haibin, Steven J. Collier, Jovana NAZOR, Joly SUKUMARAN, Derek SMITH, Jeffrey C. MOORE, Gregory HUGHES, Jacob JANEY, Gjalt HUISMAN, Scott NOVICK, Nicholas AGARD, Oscar ALVIZO, Gregory COPE, Wan Lin YEO, Stephanie NG
-
Publication number: 20130302349Abstract: This disclosure relates to novel peptide agents, e.g., antibodies and antigen-binding fragments thereof, that bind hemagglutinin protein of influenza viruses, and methods of their use.Type: ApplicationFiled: March 14, 2013Publication date: November 14, 2013Applicant: Visterra, Inc.Inventors: Zachary Shriver, Karthik Viswanathan, Vidya Subramanian, Sasisekharan Raguram
